Literature DB >> 30273074

Serial profile of flow-mediated dilatation in primigravida for prediction of preeclampsia and gestational hypertension.

Anita S Malhotra1, Poonam Goel2, Archana Chaudhary1, Suman Kochhar3, Gurjit Kaur1, Anumeha Bhagat1.   

Abstract

OBJECTIVE: Assessment of endothelial dysfunction for prediction of gestational hypertension/preeclampsia (GH/PE).
METHODS: Serial assessment of flow-mediated vasodilatation (FMD) of brachial artery was done in first, second, and third trimesters, and within 6 weeks of delivery in primigravida (n = 654). Logistic regression was used to assess the predictive value of FMD for the development of GH/PE.
RESULTS: Significant fall in FMD was observed from first trimester to third trimester but decrease in FMD in GH/PE group (57%) was more marked as compared to normal (39%) (p < 0.01). FMD (third trimester) was able to predict the development of GH/PE (OR = 1.303; 95% CI 1.088-1.562; p = 0.004).
CONCLUSIONS: FMD can be used as a non-invasive marker to predict the development of GH/PE.

Entities:  

Keywords:  Primigravida; endothelial dysfunction; flow-mediated dilatation; gestational hypertension; preeclampsia

Mesh:

Year:  2018        PMID: 30273074     DOI: 10.1080/10641955.2018.1524480

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  2 in total

1.  Generating evidence on screening, diagnosis and management of non-communicable diseases during pregnancy; a scoping review of current gap and practice in India with a comparison of Asian context.

Authors:  Theophilus Lakiang; Sonali Abner Daniel; Kauma Kurian C; Minashree Horo; Shumayla Shumayla; Sunil Mehra
Journal:  PLoS One       Date:  2021-02-01       Impact factor: 3.240

Review 2.  Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System.

Authors:  Szymon Mućka; Martyna Miodońska; Grzegorz K Jakubiak; Monika Starzak; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2022-09-07       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.